Design Therapeutics, Inc.

Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a small-molecule platform designed to target the underlying cause of inherited nucleotide repeat expansion diseases. Its programs aim to modulate abnormal gene expression and restore cellular health in disorders such as Friedreich ataxia, fragile X syndrome, myotonic dystrophy type-1, Fuchs endothelial corneal dystrophy, and Huntington's disease.

17.14

17.14

— Design Therapeutics, Inc.
%
GeneTAC® platform0% Small-molecule gene-targeted chimera molecules designed to selectively target expanded repeat sequences and modulate gene expression.
Clinical-stage product candidates0% Lead programs advancing through nonclinical and clinical development for inherited nucleotide repeat expansion diseases.
Discovery and preclinical pipeline0% Earlier-stage programs intended to expand the GeneTAC® portfolio into additional genetic diseases.
Collaborative development rights0% Selective partnering arrangements for disease areas or geographies where a strategic partner can accelerate development and commercialization.

Design Therapeutics does not sell commercial products today; its direct counterparties are regulators, clinical...

  • Patients with genetic repeat-expansion diseasesprimary

    Potential future patients in diseases such as Friedreich ataxia, fragile X syndrome, DM1, FECD, and Huntington's disease who would use approved GeneTAC therapies.

  • Physicians and key opinion leadersprimary

    Specialists and clinical experts who inform program design, trial endpoints, and eventual prescribing behavior.

  • Strategic biopharma collaboratorssecondary

    Partners that may help fund, develop, or commercialize programs in selected indications or geographies.

  • Clinical research ecosystemsecondary

    CROs, trial sites, and manufacturing vendors that execute studies and supply development materials.

The company is headquartered in the United States and currently operates as a U.S.-based clinical-stage developer with...

  • •Headquartered in the United States
  • •No product revenue disclosed to date
  • •Clinical and regulatory activity is centered on U.S. development
  • •May partner outside the U.S. for selected indications or regions
  • •Future commercialization geography will depend on approvals and strategy

Design Therapeutics is focused on advancing the GeneTAC platform through preclinical and clinical development while...

01
Advance lead GeneTAC programs into and through the clinicshort-term

Clinical proof-of-concept is the key value inflection for a platform company with no approved products.

02
Broaden the pipeline beyond initial lead indicationsmedium-term

A broader portfolio increases the chance that the platform can address multiple orphan genetic diseases.

03
Pursue selective collaborations and future commercialization optionsmedium-term

Partnerships can provide capital, expertise, and regional reach while preserving upside in core markets.

The company is pre-revenue, loss-making, and dependent on successful clinical development, regulatory approval, and...

critical

Clinical development failure

The company must prove safety and efficacy in human trials before any commercialization is possible.

Scope
Lead GeneTAC programs and future pipeline candidates
Materiality
high
high

Funding and dilution risk

The company has recurring losses and will need substantial capital to fund trials and commercialization.

Scope
Operating runway and future equity raises
Materiality
high
high

Third-party execution risk

CROs, manufacturers, and clinical sites are essential to development and can delay timelines if they underperform.

Scope
Clinical trials, nonclinical studies, and manufacturing
Materiality
high
high

Competitive displacement

Larger or better-funded companies may develop more effective or faster-to-market therapies.

Scope
Repeat-expansion disease space and gene-targeted therapeutics
Materiality
medium
medium

Regulatory and reimbursement uncertainty

Approval timing, label scope, and payer coverage will determine whether any approved therapy can reach patients profitably.

Scope
FDA, EMA, and future commercial access
Materiality
medium
Accrued research and development expenses
Can affect quarterly operating loss and balance sheet accruals
Clinical trial cost estimation
Can create volatility in R&D expense recognition
Collaboration and license accounting
Could materially affect future revenue timing
Going-concern and liquidity disclosures
Important for assessing financing risk and runway

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

Rein Therapeutics, Inc.

RNTX · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Definium Therapeutics, Inc.

DFTX · Medicinal Chemicals & Botanical Products

: 28.4.2026